期刊文献+

琥珀酸美托洛尔有关物质的结构分析 被引量:3

The Structure Analysis of the Related Substances of Metoprolol Succinate
下载PDF
导出
摘要 为了对琥珀酸美托洛尔产品中的杂质进行定量控制,对美国和英国药典中涉及的13种有关物质进行了溯源分析,开发设计合成路线并完成了对其中4种有关物质的合成,通过核磁共振和质谱确定了其化学结构.在美托洛尔的制备中,发现了1种从未被报道的、含量较高的杂质(命名为Dimer),并对该杂质进行了分离富集,通过核磁共振和质谱确定了其化学结构.根据该杂质的结构分析了其产生的原因,在此基础上,通过改变实验条件,成功地将琥珀酸美托洛尔中该杂质的含量控制在0.1%以下. To perform the quality control of metoprolol succinate,the generations of the impurities reported by USP and EP were analyzed.The synthetic routes of four impurities were designed.Impurities were prepared successfully and their structures were comfirmed by1HNMR and MS.During the scale-up manufacturing,an unreported new impurity(named Dimer) was found,and it was isolated from the final product.The chemical structure of the Dimer was elucidated,and the source of its generation was analyzed.With these results of the experiments,the reaction condition was optimized,and the content of the impurity was controlled successfully below 0.1 % in the final product.
出处 《河北师范大学学报(自然科学版)》 CAS 北大核心 2012年第3期269-274,共6页 Journal of Hebei Normal University:Natural Science
基金 河北省科技研究与发展计划(09276410D)
关键词 琥珀酸美托洛尔 杂质 合成 表征 metoprolol succinate impurity synthesis identification
  • 相关文献

参考文献14

  • 1周娜,光雪峰.琥珀酸美托洛尔片在高血压病治疗中的优势[J].中国医药导航,2008,10(6):868-869.
  • 2管高峰,李正武.琥珀酸美托洛尔缓释片降压效果评价[J].检验医学与临床,2009,6(23):1989-1990. 被引量:10
  • 3GYLLENHAAL O, VESSMAN J. Potential of Packed Column Supereritieal Fluid Chromatography for the Separation of Meto- prolol from Closely Related Compounds [J ]. Journal of Chromatography A, 1999,839:141-148.
  • 4JACKMAN G P, IAKOVIDIS D, TRACY L. Systhesis, β-adrenoceptor Pharmacology and Toxicology of S-( - )-l-(4-(2- ethoxyethoxy) phenoxy) -2-hydroxy-3- (2- (3,4-dimethoxyphenyl) ethylamino) Propane Hydrochloride, a Short Acting βl -specific Antagonist [J]. European Journal of Medicinal Chemistry,2002,37:731-741.
  • 5田建文,张小林.美托洛尔合成研究的最新进展[J].江西化工,2003,19(1):4-6. 被引量:5
  • 6黄嘉梓 徐镰 胡呜.选择性卢一受体阻滞剂美多心安的合成.中国医药工业杂志,1983,:5-6.
  • 7BEVINAKATTI H S, BANERJI A A. Practical Chemoenzymatic Synthesis of Both Enantiomers of Propranolol [J]. J Org Chem, 1991,56 : 5372-5375.
  • 8LOVGREN K, HEDBERG A. Adrenergic Receptor Agonists, Benzofuranylethanolamines [ J ]. J Med Chem, 1980,23 : 624-627.
  • 9YI Wei, CAO Rihui, PENG Wenlie. Synthesis and Biological Evaluation of Novel 4-hydroxybenzaldehyde Derivatives as Tyrosi- nase Inhibitors [J ]. Eur J of Med Chem,2010,45:639-646.
  • 10SRIVASTAVE S, BHANDARI K. Synthesis, Anorexigenic Activity and QSNR of Substituted Aryloxypropanolamines [J ]. Med Chem Res,2004,13:631-642.

二级参考文献7

  • 1陈冠荣.《化工百科全书》第17卷[M].北京:化学工业出版社,1998年.1117-1191页.
  • 2恽魁宏.《有机化学》[M].北京:高等教育出版社第二版,1990年.330—400页.
  • 3.[P].JPN,KOKAI(日本公开特许) 58159446..
  • 4黄嘉梓 等.选择性β受体阻滞美多心安的合成[J].医药工业,1983,(1):5-6.
  • 5Frishman WH, Hainer JW, Sugg J. M-FACT Study Group. A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the Metoprolol Succinate Felodipine Antihypertension Combination Trial[J]. Am J Hypertension,2006,19:388-395.
  • 6Sandberg A, Abrahamssom B, Regardh CG, et al. Pharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR/Zok;a review article[J]. J Clin Pharmacol, 1990,30 : 2-16.
  • 7蒋立新.琥珀酸美托洛尔缓释片(倍他乐克缓释片)药理学特点和降压疗效[J].中国医学论坛报,2005,31(39):42-42.

共引文献14

同被引文献17

  • 1姜志荣,马红婷,张莉.美托洛尔治疗高血压临床观察[J].中国高血压杂志,1994,2(2):125-126. 被引量:2
  • 2胡贞铨,李奇成,饶文康,刘顶华,张国英,赵南征.美托洛尔逆转高血压性左心室肥厚的效应[J].中国高血压杂志,1994,2(2):126-127. 被引量:2
  • 3萧爽.美托洛尔[J].中国医院药学杂志,1994,14(6):285-286. 被引量:1
  • 4周娜,光雪峰.琥珀酸美托洛尔片在高血压病治疗中的优势[J].中国医药导航,2008,10(6):868-869.
  • 5黄嘉梓,徐镰,胡鸣.β-受体阻滞剂美多心安的合成[J].中国医药工业杂志,1983(1):5-6.
  • 6Kreutzer J, Tam W, Garner J, et al. Hydroformylation process utilizing multidentate phosphite ligands: EP, 1214282 [ P ]. 2005 - 02 - 23.
  • 7Sawyer D. A, Beams R. M. , Blackwell G. J. , et al. Development of a no- vel series of trialkoxyaryl derivatives as specific and competitive antago- nists of platelet activating factor [ J ]. Journal of Medicinal Chemistry, 1995,38(12) :2130 -2137.
  • 8European Pharmacopoeia Commission. European Pharmacopoeia 7.0 [S].Strasbourg: European Directorate for the Quality Control of Medicines, 2010: 2495-2497.
  • 9KREUTZER J, TAM W, GARNER J, et al. Hydroformylation process utilizing multidentate phosphite ligands: EP, 1214282 [P]. 2005-02-23.
  • 10SAWYER D A, BEAMS R M, BLACKWELL G J, et al.Development of a novel series of trialkoxyaryl derivatives as specific and competitive antagonists of platelet activating factor[J].J Med Chem,1995,38(12):2130-2137.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部